Neurology News

The FDA has approved Lamzede, an enzyme replacement therapy for non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients, Chiesi Global Rare Diseases announced in a press release.

About three in 10 adults with chronic pain who live in states with medical cannabis laws reported using cannabis to manage their pain, according to researchers, highlighting the need for more research on the subject.

High levels of patient engagement with nurse navigators after hospitalization for hemorrhagic stroke led to less disability and lower readmission rates after 90 days, according to research presented at International Stroke Conference.

Ryne Biotechnology Inc. has announced a $4 million Clinical Stage Research Program grant from the California Institute for Regenerative Medicine to advance its lead candidate for the treatment of Parkinson’s disease.

The FDA has granted orphan drug designation to Avidity Biosciences Inc. for AOC 1020, its novel RNA therapeutic to treat facioscapulohumeral muscular dystrophy.

The proportion of missed stroke diagnoses was more than four times higher in postpartum women with acute stroke compared with rates reported in nonmaternal populations, according to research presented at International Stroke Conference.

The FDA has granted 510(k) clearance to an at-home test device that can diagnose obstructive sleep apnea and other sleep-related breathing disorders, according to a press release.

Cerebral amyloid angiopathy was associated with a higher risk for isolated nontraumatic subdural hemorrhage in two large, independent cohorts, according to research presented at International Stroke Conference.

The American Medical Association and 118 other medical societies, including the American College of Rheumatology, are urging CMS to finalize proposed rules aiming to reform prior authorization, according to a press release.

The national Further the Objective and Clinical Understanding of Cognivue Study drew a 37% research participation rate from individuals in underserved and underrepresented populations, the neuroscience company reported in a press release.